The present findings suggested that MARCKSL1, a potential therapeutic target for hepatocellular carcinoma and MVI progression, may be crucial for improving therapeutic strategies and clinical outcomes, particularly for patients with MVI. This evidence concerns the gene MARCKSL1 and hepatocellular carcinoma.